What is the TG Therapeutics Inc (TGTX) price today?

The price of TG Therapeutics Inc (TGTX) today is $36.96. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/TGTX

Buy & Sell TG Therapeutics Inc (TGTX) – TG Therapeutics Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

TG Therapeutics (TGTX) trades at $35.33, up 3.0% on the day, with strong analyst support (84.6% buy ratings) driven by robust revenue growth from its multiple sclerosis drug Briumvi. The company reported $616.3M in 2025 revenue with exceptional 72.56% net profit margins, though earnings have been volatile with recent misses. Key catalysts include the subcutaneous Briumvi Phase 3 trial completion (data expected late 2026/early 2027) and $500M in non-dilutive capital secured in March 2026.

Outlook remains positive with Briumvi's market share gains and $875-900M 2026 revenue guidance, but risks include clinical trial execution, earnings volatility, and high valuation multiples (EV/EBITDA 44.76). The stock offers growth exposure to a successful MS franchise with financial flexibility from recent capital raises.

Read full analysis

Key Stats

Market Cap
$5.90B
Sector
Health
3M Drawdown
-14.83%
Enterprise Value
$6.01B
Dividend Yield
-

$36.96

52W Low: $26.39

11 Aug 2025

52W High: $45.51

30 Apr 2025

TG Therapeutics Inc (TGTX) is currently valued at a market capitalization of $5.90B, with an enterprise value of $6.01B. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.39 and a high of $45.51, highlighting its annual price range. Over the past three months, TG Therapeutics Inc has recorded a drawdown of -14.83%, reflecting recent price volatility.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Technical Indicators

Overall Summary

Bearish (3)Neutral (10)Bullish (12)

News

Benzinga1 year ago

Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio?

Globe Newswire1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Globe Newswire1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

The Motley Fool2 year ago

"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Globe Newswire2 year ago

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$5.90B
Sector
Health
3M Drawdown
-14.83%
Enterprise Value
$6.01B
Dividend Yield
-

$36.96

52W Low: $26.39

11 Aug 2025

52W High: $45.51

30 Apr 2025

Let’s invest in this asset by signing up or download!

Buy & Sell TG Therapeutics Inc (TGTX) – TG Therapeutics Inc Price Today

Aura AI Summary

Key Stats

About TG Therapeutics Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store